Результаты исследований: Научные публикации в периодических изданиях › статья
Biofilm infections between Scylla and Charybdis: interplay of host antimicrobial peptides and antibiotics. / Черныш, Сергей Иванович; Яковлев, Андрей Юрьевич; Гордя, Наталья Александровна; Тулин, Дмитрий Валентинович.
в: Infection and Drug Resistance, Том 11, 09.04.2018, стр. 501-514.Результаты исследований: Научные публикации в периодических изданиях › статья
}
TY - JOUR
T1 - Biofilm infections between Scylla and Charybdis: interplay of host antimicrobial peptides and antibiotics
AU - Черныш, Сергей Иванович
AU - Яковлев, Андрей Юрьевич
AU - Гордя, Наталья Александровна
AU - Тулин, Дмитрий Валентинович
N1 - Funding Information: This study was supported by a grant from the Russian Science Foundation (http://rscf.ru/, grant number 16-14-00048). The funder had no role in study design, data collection and analysis and decision to publish or preparation of the manuscript. The authors are grateful to Resource Centers “Development of molecular and cellular technologies”, “Chemical analysis and materials research” and “Culture collections of microorganisms” of St. Petersburg State University Research Park for technical assistance.
PY - 2018/4/9
Y1 - 2018/4/9
N2 - Purpose: The aim of this study is to improve the anti-biofilm activity of antibiotics. We hypothesized that the antimicrobial peptide (AMP) complex of the host’s immune system can be used for this purpose and examined the assumption on model biofilms. Methods: FLIP7, the AMP complex of the blowfly Calliphora vicina containing a combination of defensins, cecropins, diptericins and proline-rich peptides was isolated from the hemolymph of bacteria-challenged maggots. The complex interaction with antibiotics of various classes was studied in biofilm and planktonic cultures of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii by the checkerboard method using trimethyl tetrazolium chloride cell viability and crystal violet biofilm eradication assays supplemented with microscopic analysis. Results: We found that FLIP7 demonstrated: high synergy (fractional inhibitory concentration index <0.25) with meropenem, amikacin, kanamycin, ampicillin, vancomycin and cefotaxime; synergy with clindamycin, erythromycin and chloramphenicol; additive interaction with oxacillin, tetracycline, ciprofloxacin and gentamicin; and no interaction with polymyxin B. The interaction in planktonic cell models was significantly weaker than in biofilms of the same strains. The analysis of the dose-effect curves pointed to persister cells as a likely target of FLIP7 synergistic effect. The biofilm eradication assay showed that the effect also caused total destruction of S. aureus and E. coli biofilm materials. The effect allowed reducing the effective anti-biofilm concentration of the antibiotic to a level well below the one clinically achievable (2-3 orders of magnitude in the case of meropenem, ampicillin, cefotaxime and oxacillin). Conclusion: FLIP7 is a highly efficient host antimicrobial system helping antibiotics to overcome biofilm barriers through persisters’ sensitization and biofilm material destruction. It is promising for the treatment of biofilm infections as an adjuvant of various small-molecule antibiotics.
AB - Purpose: The aim of this study is to improve the anti-biofilm activity of antibiotics. We hypothesized that the antimicrobial peptide (AMP) complex of the host’s immune system can be used for this purpose and examined the assumption on model biofilms. Methods: FLIP7, the AMP complex of the blowfly Calliphora vicina containing a combination of defensins, cecropins, diptericins and proline-rich peptides was isolated from the hemolymph of bacteria-challenged maggots. The complex interaction with antibiotics of various classes was studied in biofilm and planktonic cultures of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii by the checkerboard method using trimethyl tetrazolium chloride cell viability and crystal violet biofilm eradication assays supplemented with microscopic analysis. Results: We found that FLIP7 demonstrated: high synergy (fractional inhibitory concentration index <0.25) with meropenem, amikacin, kanamycin, ampicillin, vancomycin and cefotaxime; synergy with clindamycin, erythromycin and chloramphenicol; additive interaction with oxacillin, tetracycline, ciprofloxacin and gentamicin; and no interaction with polymyxin B. The interaction in planktonic cell models was significantly weaker than in biofilms of the same strains. The analysis of the dose-effect curves pointed to persister cells as a likely target of FLIP7 synergistic effect. The biofilm eradication assay showed that the effect also caused total destruction of S. aureus and E. coli biofilm materials. The effect allowed reducing the effective anti-biofilm concentration of the antibiotic to a level well below the one clinically achievable (2-3 orders of magnitude in the case of meropenem, ampicillin, cefotaxime and oxacillin). Conclusion: FLIP7 is a highly efficient host antimicrobial system helping antibiotics to overcome biofilm barriers through persisters’ sensitization and biofilm material destruction. It is promising for the treatment of biofilm infections as an adjuvant of various small-molecule antibiotics.
KW - Antibiotics
KW - Biofilms
KW - Calliphora vicina
KW - Insect antimicrobial peptides
KW - Persisters
KW - Synergy
KW - insect antimicrobial peptides
KW - synergy
KW - CLINICAL PHARMACOKINETICS
KW - COMBINATION
KW - GRAM-NEGATIVE BACTERIA
KW - THERAPY
KW - persisters
KW - CRITICALLY-ILL PATIENTS
KW - antibiotics
KW - biofilms
UR - https://www.dovepress.com/getfile.php?fileID=41407
UR - http://www.scopus.com/inward/record.url?scp=85046337157&partnerID=8YFLogxK
UR - http://www.mendeley.com/research/biofilm-infections-between-scylla-charybdis-interplay-host-antimicrobial-peptides-antibiotics
U2 - http://dx.doi.org/10.2147/idr.s157847
DO - http://dx.doi.org/10.2147/idr.s157847
M3 - Article
C2 - 29674848
VL - 11
SP - 501
EP - 514
JO - Infection and Drug Resistance
JF - Infection and Drug Resistance
SN - 1178-6973
ER -
ID: 33910415